The low-throughput, resource-intensive process of antibody variant characterization can be a costly bottleneck in the discovery pipeline. Twist High Throughput Antibody Production is a gene-to-protein workflow that relieves this bottleneck by producing tens to thousands of diverse antibodies for screening biophysical and pharmacokinetic properties. Twist’s silicon- based DNA synthesis platform can precisely write thousands of genes per run, enabling the rapid and high-throughput production of antibodies for discovery and screening.

The efficiency and ease of use of the CRISPR-Cas9 system has led to its rapid adoption as a robust and versatile genome editing tool. However, limitations remain - not least the constraint of the Cas9 protospacer adjacent motif (PAM), which limits the locations that can be targeted.    One way to overcome this is to explore the natural variation afforded by other CRISPR-associated (Cas) enzymes - which provide a rich resource for the development of RNA-guided genome editing tools with diverse and potentially beneficial properties.

Biology is reshaping our future, from our medicines to our food, fuels, homes, and even clothes. But the power to engineer and re-design biology comes with significant responsibility. How can we ensure the bio-engineering tools aren't misused or create accidentally harmful materials? How can we ensure workers, our society, and our planet are all protected? In the inaugural Built with Biology Podcast episode, host Fiona Mischel speaks with James Diggans, Head of Biosecurity at Twist Bioscience. What is biosecurity, why does it matter, and how it could impact your day-to-day life? Get all your questions answered and more!